Company Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.
It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.
It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths.
Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands.
The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations.
Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands.
The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 1981 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 1,783 |
| CEO | Olivier Loeillot |
Contact Details
Address: Building 1, Suite 100 Waltham, Massachusetts 02453 United States | |
| Phone | 781 250 0111 |
| Website | repligen.com |
Stock Details
| Ticker Symbol | RGEN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000730272 |
| CUSIP Number | 759916109 |
| ISIN Number | US7599161095 |
| Employer ID | 04-2729386 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Olivier Loeillot | President, Chief Executive Officer and Director |
| Anthony J. Hunt | Executive Chair |
| Jason K. Garland | Chief Financial Officer and Chief Compliance Officer |
| James R. Bylund | Chief Operating Officer |
| Ralf Kuriyel | Senior Vice President of Research and Development |
| Keith Lee Robinson | Chief Information Officer |
| Sondra S. Newman | Global Head of Investor Relations |
| Kimberly A. Cornwell | Global Head of Legal |
| Neil Whitfield | Vice President and Global Head of Sales |
| Teresa Ferragamo | Senior Director of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 21, 2024 | 144 | Filing |
| Nov 18, 2024 | 10-Q | Quarterly Report |
| Nov 18, 2024 | 10-Q/A | [Amend] Quarterly report |
| Nov 18, 2024 | 10-Q/A | [Amend] Quarterly report |
| Nov 18, 2024 | 10-K/A | [Amend] Annual report |
| Nov 18, 2024 | 10-Q/A | [Amend] Quarterly report |
| Nov 18, 2024 | 10-Q/A | [Amend] Quarterly report |
| Nov 18, 2024 | 10-Q/A | [Amend] Quarterly report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |